Infective Exacerbations of Chronic Bronchitis : Relation between Bacteriologic Etiology and Lung Function

TL;DR: Amoxycill in 1 g bd is clinically and bacteriologically as effective as amoxycillin 500 mg tds in the treatment of AECB, and the two dosage regimens show a similar safety profile.

TL;DR: Amoxycillin was at least as effective clinically and as safe as amoxycilin/ clavulanate in the treatment of acute exacerbations of COPD in mild to moderate patients in primary care.

TL;DR: It can be concluded that prulifloxacin 600 mg once daily is a new therapeutic prospect in the antimicrobial therapy of AECB, since good patient compliance is a key factor in the successful treatment of any infection, and the once daily treatment may have some compliance advantages compared to the twice-daily treatment with agents such as ciprofloxacIn or co-amoxiclav.

TL;DR: Pneumoniae constituye el microorganismo bacteriano that con mas frecuencia se aisla de los pacientes that sufren agudizaciones of the bronquitis cronica that pueden ser tratados ambulatoriamente.

TL;DR: There was a significant benefit associated with antibiotic and Peak flow recovered more rapidly with antibiotic treatment than with placebo, and side effects were uncommon and did not differ between antibiotic and placebo.

TL;DR: Severe or fatal obstructive lung disease could be prevented by screening smokers' lung function in early middle age if those with reduced function could be induced to stop smoking.

TL;DR: The lower airways of asymptomatic chronic obstructive pulmonary disease (COPD) patients can be colonized by bacteria, mainly Haemophilus influenza, Streptococcus pneumoniae, and Moraxella catarrhalis, but the role of lower airway bacteria in stable and exacerbated COPD has not been well defined.